A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

This publication has 42 references indexed in Scilit:

• Protective Efficacy of a Single Immunization of a Chimeric Adenovirus Vector-Based Vaccine against Simian Immunodeficiency Virus Challenge in Rhesus Monkeys
  Journal of Virology, 2009
• Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans
  Nature Medicine, 2009
• Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge
  Virology, 2008
• HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
  The Lancet, 2008
• Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
  Published by Elsevier ,2008
• Comparison of multiple vaccine vectors in a single heterologous prime-boost trial
  Vaccine, 2008
• Biodistribution and Toxicological Safety of Adenovirus Type 5 and Type 35 Vectored Vaccines Against Human Immunodeficiency Virus-1 (HIV-1), Ebola, or Marburg Are Similar Despite Differing Adenovirus Serotype Vector, Manufacturer's Construct, or Gene Inserts
  Journal of Immunotoxicology, 2008
• Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 DNA Candidate Vaccine
  The Journal of Infectious Diseases, 2006
• Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus Vector
  The Journal of Infectious Diseases, 2006
• A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial
  Clinical and Vaccine Immunology, 2006